These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19699593)

  • 1. A placebo-controlled trial of buspirone for the treatment of marijuana dependence.
    McRae-Clark AL; Carter RE; Killeen TK; Carpenter MJ; Wahlquist AE; Simpson SA; Brady KT
    Drug Alcohol Depend; 2009 Nov; 105(1-2):132-8. PubMed ID: 19699593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial.
    McRae-Clark AL; Baker NL; Gray KM; Killeen TK; Wagner AM; Brady KT; DeVane CL; Norton J
    Drug Alcohol Depend; 2015 Nov; 156():29-37. PubMed ID: 26386827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders].
    Lemoine P; Rouillon F; Pouget D
    Encephale; 1996; 22(6):461-7. PubMed ID: 10901839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buspirone for treatment of marijuana dependence: a pilot study.
    McRae AL; Brady KT; Carter RE
    Am J Addict; 2006; 15(5):404. PubMed ID: 16966201
    [No Abstract]   [Full Text] [Related]  

  • 5. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder.
    Lader M; Scotto JC
    Psychopharmacology (Berl); 1998 Oct; 139(4):402-6. PubMed ID: 9809861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam.
    Bourin M; Malinge M
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul; 19(4):567-75. PubMed ID: 8588056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled comparison of buspirone and oxazepam in generalized anxiety.
    Ansseau M; Papart P; Gérard MA; von Frenckell R; Franck G
    Neuropsychobiology; 1990-1991; 24(2):74-8. PubMed ID: 2134114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety.
    Sramek JJ; Frackiewicz EJ; Cutler NR
    Clin Ther; 1997; 19(3):498-506. PubMed ID: 9220214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
    Levin FR; Mariani JJ; Brooks DJ; Pavlicova M; Cheng W; Nunes EV
    Drug Alcohol Depend; 2011 Jul; 116(1-3):142-50. PubMed ID: 21310551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of buspirone in smoking cessation: a placebo-controlled trial.
    Schneider NG; Olmstead RE; Steinberg C; Sloan K; Daims RM; Brown HV
    Clin Pharmacol Ther; 1996 Nov; 60(5):568-75. PubMed ID: 8941030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of withdrawal of buspirone and diazepam: a placebo controlled study.
    Fontaine R; Beaudry P; Beauclair L; Chouinard G
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(2-3):189-97. PubMed ID: 2888159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buspirone: anxiolytic?
    Pecknold JC; Familamiri P; Chang H; Wilson R; Alarcia J; McClure DJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):639-42. PubMed ID: 2868495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multisite, randomized, double-blind, placebo-controlled pilot clinical trial to evaluate the efficacy of buspirone as a relapse-prevention treatment for cocaine dependence.
    Winhusen TM; Kropp F; Lindblad R; Douaihy A; Haynes L; Hodgkins C; Chartier K; Kampman KM; Sharma G; Lewis DF; VanVeldhuisen P; Theobald J; May J; Brigham GS
    J Clin Psychiatry; 2014 Jul; 75(7):757-64. PubMed ID: 24911028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.
    D'Souza DC; Cortes-Briones J; Creatura G; Bluez G; Thurnauer H; Deaso E; Bielen K; Surti T; Radhakrishnan R; Gupta A; Gupta S; Cahill J; Sherif MA; Makriyannis A; Morgan PT; Ranganathan M; Skosnik PD
    Lancet Psychiatry; 2019 Jan; 6(1):35-45. PubMed ID: 30528676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone.
    Rickels K; Schweizer E; Csanalosi I; Case WG; Chung H
    Arch Gen Psychiatry; 1988 May; 45(5):444-50. PubMed ID: 2895993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
    Pollack MH; Worthington JJ; Manfro GG; Otto MW; Zucker BG
    J Clin Psychiatry; 1997; 58 Suppl 11():19-23. PubMed ID: 9363044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Buspirone in the treatment of alcohol dependence: a placebo-controlled trial.
    Malec E; Malec T; Gagné MA; Dongier M
    Alcohol Clin Exp Res; 1996 Apr; 20(2):307-12. PubMed ID: 8730222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of buspirone for relapse-prevention in adults with cocaine dependence: an efficacy trial conducted in the real world.
    Winhusen T; Brady KT; Stitzer M; Woody G; Lindblad R; Kropp F; Brigham G; Liu D; Sparenborg S; Sharma G; Vanveldhuisen P; Adinoff B; Somoza E
    Contemp Clin Trials; 2012 Sep; 33(5):993-1002. PubMed ID: 22613054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences in cannabis use disorder treatment: Change readiness and taking steps predict worse cannabis outcomes for women.
    Sherman BJ; Baker NL; McRae-Clark AL
    Addict Behav; 2016 Sep; 60():197-202. PubMed ID: 27156221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals.
    McRae AL; Sonne SC; Brady KT; Durkalski V; Palesch Y
    Am J Addict; 2004; 13(1):53-63. PubMed ID: 14766438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.